Reading Time: 5 minutes Last year was a really exciting year for MND clinical trials, with more trials recruiting in the UK than ever before, some promising results being released, and some drugs being approved by certain regulatory authorities. We hope that the momentum will continue this year and want to highlight just some of the updates we are…
Reading Time: 4 minutes Last year was a really exciting year for MND clinical trials, with more trials recruiting in the UK than ever before, some promising results being released, and some drugs being approved by certain regulatory authorities. We hope that the momentum will continue this year and want to highlight just some of the updates we are…
Reading Time: 6 minutes It has been suggested that there might be a pre-symptomatic stage of MND, where the disease is active and occurring within a person but no symptoms are showing. There is currently little research in this area and a lack of evidence of a pre-symptomatic stage of the disease. However, if it can be shown that there is a pre-symptomatic stage which can be measured, this could be very useful in helping people with MND to get treatment as early as possible. Dr Michael Benatar, from the University of Miami, has been looking into this by studying the development of MND and how the disease presents in people who have a high risk of developing it.
Reading Time: 6 minutes Over the last year ALS/MND clinical trials have taken centre stage, with more trials than ever opening for recruitment in the UK, the news of promising results from some trials and the approval of drugs by some regulatory authorities. With the year coming to an end, we thought we would roundup some recent clinical trial updates that were presented at the 33rd International Symposium on ALS/MND.
Reading Time: 5 minutes The top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium on ALS/MND. As part of the clinical trials session, the scientific leads Dr Gilbert Bensimon and Professor Nigel Leigh discussed the study design and outcomes (C03). MIROCALS was an 18-month,…
Reading Time: 2 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract. As a new feature of the Symposium Blogathon, we got in touch…
Reading Time: 5 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract. Clinical trials are research studies in human volunteers that determine whether…
Reading Time: 5 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract. Clinical trials are research studies in human volunteers that determine whether…
Reading Time: 5 minutes In this guest blog written by Harry Bowles and Sarah Opie-Martin from King’s College London they discuss their MND research poster which was presented at the European Network to Cure ALS (ENCALS) meeting in June 2022. Randomised, double blind trials are the gold standard During a clinical trial, a group of volunteers with ALS are…
Reading Time: 6 minutes Update 21/09/2022: The results of the VALOR trial and its open label extension were published in the New England Journal of Medicine. These results give mounting confidence that Tofersen is having both a biological and a beneficial effect in people living with SOD1 MND. You can read more about the results below. The Motor Neurone…
